547 related articles for article (PubMed ID: 16879677)
21. Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.
Horvath LG; McCaughan BC; Stockle M; Boyer MJ
Intern Med J; 2002 Mar; 32(3):79-83. PubMed ID: 11885847
[TBL] [Abstract][Full Text] [Related]
22. Primary chemotherapy in patients with nonseminomatous germ cell tumors of the testis and biological disease only after orchiectomy.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1996 Apr; 155(4):1296-8. PubMed ID: 8632558
[TBL] [Abstract][Full Text] [Related]
23. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
24. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
25. Resection of pulmonary metastases following chemotherapy for high stage testicular tumors.
Eskicorapci SY; Ekici S; Atsu MN; Dogan R; Ozen H
Int J Urol; 2004 Aug; 11(8):634-9. PubMed ID: 15285754
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours.
Napier MP; Naraghi A; Christmas TJ; Rustin GJ
Br J Cancer; 2000 Nov; 83(10):1274-80. PubMed ID: 11044349
[TBL] [Abstract][Full Text] [Related]
27. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
[TBL] [Abstract][Full Text] [Related]
28. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.
Kellie SJ; Boyce H; Dunkel IJ; Diez B; Rosenblum M; Brualdi L; Finlay JL
J Clin Oncol; 2004 Mar; 22(5):846-53. PubMed ID: 14990640
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study on poor-risk patients with non-seminomatous germ cell tumor].
Okamura K; Takashi M; Hibi H; Tsuji Y; Shimoji T; Ohshima S; Takagi Y; Suzuki Y; Mizutani K; Ono Y; Kato T; Kobayashi M
Hinyokika Kiyo; 1998 Apr; 44(4):265-72. PubMed ID: 9617623
[TBL] [Abstract][Full Text] [Related]
30. Integration of surgery and systemic therapy: results and principles of integration.
Donohue JP; Leviovitch I; Foster RS; Baniel J; Tognoni P
Semin Urol Oncol; 1998 May; 16(2):65-71. PubMed ID: 9649229
[TBL] [Abstract][Full Text] [Related]
31. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
Carver BS; Serio AM; Bajorin D; Motzer RJ; Stasi J; Bosl GJ; Vickers AJ; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5603-8. PubMed ID: 17998544
[TBL] [Abstract][Full Text] [Related]
32. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases.
Dieckmann KP; Albers P; Classen J; De Wit M; Pichlmeier U; Rick O; Müllerleile U; Kuczyk M
J Urol; 2005 Mar; 173(3):824-9. PubMed ID: 15711278
[TBL] [Abstract][Full Text] [Related]
33. Surgery for testicular cancer: indication, results and technical aspects.
Khouni H; Ghozzi S; Ramzi K; Smaali CH; Majed H; Ben Rais N
Tunis Med; 2005 Dec; 83 Suppl 12():78-83. PubMed ID: 16430075
[TBL] [Abstract][Full Text] [Related]
34. Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.
Shahidi M; Norman AR; Dearnaley DP; Nicholls J; Horwich A; Huddart RA
Cancer; 2002 Aug; 95(3):520-30. PubMed ID: 12209744
[TBL] [Abstract][Full Text] [Related]
35. Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy.
Copson E; McKendrick J; Hennessey N; Tung K; Mead GZ
BJU Int; 2004 Sep; 94(4):552-8. PubMed ID: 15329111
[TBL] [Abstract][Full Text] [Related]
36. Primary chemotherapy for stage 2 testis cancer.
Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
[TBL] [Abstract][Full Text] [Related]
37. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
38. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
El-Helw LM; Naik JD; Chester JD; Joffe JK; Selby PJ; Coleman RE
BJU Int; 2006 Sep; 98(3):519-25. PubMed ID: 16925746
[TBL] [Abstract][Full Text] [Related]
39. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
Modak S; Gardner S; Dunkel IJ; Balmaceda C; Rosenblum MK; Miller DC; Halpern S; Finlay JL
J Clin Oncol; 2004 May; 22(10):1934-43. PubMed ID: 15143087
[TBL] [Abstract][Full Text] [Related]
40. Management of germ cell testicular cancer with pulmonary metastases.
Schnorrer M; Ondrus D; Cársky S; Hornák M; Belan V; Kausitz J; Matośka J
Neoplasma; 1996; 43(1):47-50. PubMed ID: 8843960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
